Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Nat Rev Drug Discov ; 16(5): 297-298, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28232726

RESUMO

Growing access to diverse 'real-world' data sources is enabling new approaches to close persistent evidence gaps about the optimal use of medical products in real-world practice. Here, we argue that contrary to widespread impressions, existing FDA regulations embody sufficient flexibility to accommodate the emerging tools and methods needed to achieve this goal.


Assuntos
Ensaios Clínicos como Assunto/métodos , Desenho de Fármacos , Controle de Medicamentos e Entorpecentes , United States Food and Drug Administration/legislação & jurisprudência , Humanos , Fatores de Tempo , Estados Unidos
5.
Med Care ; 50(11): 948-53, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23047784

RESUMO

After half a century of monitoring voluntary reports of medical product adverse events, the Food and Drug Administration (FDA) has launched a long-term project to build an adverse events monitoring system, the Sentinel System, which can access and evaluate electronic health care data to help monitor the safety of regulated medical products once they are marketed. On the basis of experience gathered through a number of collaborative efforts, the Federal Partners' Collaboration pilot project, involving FDA, the Centers for Medicare & Medicaid Services, the Department of Veteran Affairs, and the Department of Defense, is already enabling FDA to leverage the power of large public health care databases to assess, in near real time, the utility of analytical tools and methodologies that are being developed for use in the Sentinel System. Active medical product safety surveillance is enhanced by use of these large public health databases because specific populations of exposed patients can be identified and analyzed, and can be further stratified by key variables such as age, sex, race, socioeconomic status, and basis for eligibility to examine important subgroups.


Assuntos
Bases de Dados Factuais , Sistemas de Informação/organização & administração , Relações Interinstitucionais , Vigilância de Produtos Comercializados/métodos , United States Food and Drug Administration/organização & administração , Adulto , Fatores Etários , Idoso , Antivirais/administração & dosagem , Antivirais/efeitos adversos , Centers for Medicare and Medicaid Services, U.S./organização & administração , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Fatores Sexuais , Fatores Socioeconômicos , Estados Unidos , United States Department of Defense/organização & administração , United States Department of Veterans Affairs/organização & administração , Adulto Jovem
7.
Pharmacoepidemiol Drug Saf ; 21 Suppl 1: 12-7, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22262588

RESUMO

The US Food and Drug Administration's Mini-Sentinel pilot program is developing an organizational structure as well as principles and policies to govern its operations. These will inform the structure and function of the eventual Sentinel System. Mini-Sentinel is a collaboration that includes 25 participating institutions. We describe the program's current organizational structure and its major principles and policies. The organization includes a coordinating center with program leadership provided by a principal investigator; a planning board and subcommittees; an operations center; and data, methods, and protocol cores. Ad hoc workgroups are created as needed. A privacy panel advises about protection of individual health information. Principles and policies are intended to ensure that Mini-Sentinel conforms to the principles of fair information practices, protects the privacy of individual health information, maintains the security and integrity of data, assures the confidentiality of proprietary information, provides accurate and timely communications, prevents or manages conflicts of interest, and preserves respect for intellectual property rights.


Assuntos
Política Organizacional , Vigilância de Produtos Comercializados/métodos , United States Food and Drug Administration , Confidencialidade/legislação & jurisprudência , Comportamento Cooperativo , Humanos , Propriedade Intelectual , Projetos Piloto , Desenvolvimento de Programas/métodos , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...